Thursday, the Food and Drug Administration named drugmakers, including Celgene Corp., Johnson & Johnson, Gilead Sciences, and Novartis AG, as companies that are potentially blocking access to samples of their drugs to delay generic competition. Generic drugmakers may not be able to develop alternatives without access to samples of branded products.